# G2B Pharma, Inc.: Form D filing

G2B Pharma, Inc., a biotechnology company in San Francisco, CA, filed a Form D with the SEC in 2013. The latest, on June 11, 2013, reports $235,000 sold of a $235,000 offering to 14 investors.

Find out what G2B Pharma, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20G2B%20Pharma%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=G2B%20Pharma%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fg2b-pharma-inc-1578421)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20G2B%20Pharma%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=G2B%20Pharma%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fg2b-pharma-inc-1578421)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in California](https://specstream.ai/data/form-d/state/california): 5,891 rows, by operating companies, filed since November 1, 2024, $138.91, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/california
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 474 LIBERTY ST., San Francisco, CA, 94114
- Phone: (415) 505-6099
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Year incorporated: 2009
- Revenue range: No Revenues
- Exemptions claimed: Rule 504
- SEC identifier (CIK): 1578421

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Jun 11, 2013 | New notice | $235,000 | $235,000 | $0 | 14 | May 31, 2013 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1578421/000157842113000001/0001578421-13-000001-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Douglas B. Evans | Executive Officer |  |

## Other biotechnology companies in California that filed recently

- [CARI Health, Inc.](https://specstream.ai/data/form-d/company/cari-health-inc-1930994) $280,000 · Nov 6, 2026
- [Ausel, Inc.](https://specstream.ai/data/form-d/company/ausel-inc-2124022) $120,000 · Nov 4, 2026
- [Trellis Bioscience, Inc.](https://specstream.ai/data/form-d/company/trellis-bioscience-inc-1162015) $9.1 million · Oct 29, 2026
- [BigHat Biosciences, Inc.](https://specstream.ai/data/form-d/company/bighat-biosciences-inc-1797256) $75.1 million · Oct 26, 2026
- [Theravie Pharma, Inc.](https://specstream.ai/data/form-d/company/theravie-pharma-inc-2160768) $750,000 · Oct 19, 2026
- [Adela, Inc.](https://specstream.ai/data/form-d/company/adela-inc-1852167) $12 million · Oct 19, 2026
- [Estuary Biotherapeutics, Inc.](https://specstream.ai/data/form-d/company/estuary-biotherapeutics-inc-2138862) $40.7 million · Oct 16, 2026
- [Renue Life Sciences, Inc.](https://specstream.ai/data/form-d/company/renue-life-sciences-inc-2158207) $250,000 · Oct 14, 2026
- [Tempest Therapeutics, Inc.](https://specstream.ai/data/form-d/company/tempest-therapeutics-inc-1544227) $7.5 million · Oct 14, 2026
- [Lionheart Health, Inc.](https://specstream.ai/data/form-d/company/lionheart-health-inc-2156758) $387,500 · Oct 7, 2026
- [Rakuten Medical, Inc.](https://specstream.ai/data/form-d/company/rakuten-medical-inc-1595215) $9 million · Oct 6, 2026
- [Zonaliz, Inc.](https://specstream.ai/data/form-d/company/zonaliz-inc-2157556) $2.5 million · Oct 5, 2026
- [Altay Therapeutics, Inc.](https://specstream.ai/data/form-d/company/altay-therapeutics-inc-2157551) $15.7 million · Oct 2, 2026
- [Sialia Therapeutics, Inc.](https://specstream.ai/data/form-d/company/sialia-therapeutics-inc-2156754) $1.5 million · Sep 29, 2026
- [Vetmab Biosciences, Inc.](https://specstream.ai/data/form-d/company/vetmab-biosciences-inc-1932050) $11.4 million · Sep 29, 2026

[Every Form D from the week of Jun 10, 2013](https://specstream.ai/data/form-d/week/2013-06-10) · [All recent filings in California](https://specstream.ai/data/form-d/state/california) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what G2B Pharma, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).